Rheumatology International

, Volume 20, Issue 4, pp 149–153 | Cite as

The new antirheumatic drug KE-298 suppresses monocyte chemoattractant protein (MCP)-1 and RANTES production in rats with adjuvant-induced arthritis and in IL-1β-stimulated synoviocytes of patients with rheumatoid arthritis

  • Tomoyuki Inoue
  • Miyuki Yamashita
  • Megumu Higaki
Original Article

Abstract.

We analyzed the effects of the new antirheumatic drug KE-298 on monocyte chemoattractant protein (MCP)-1 and regulated on activation normal T-cell expressed and secreted (RANTES) production in rats with adjuvant-induced arthritis and in interleukin (IL)-1β-stimulated rheumatoid arthritis (RA) synoviocytes. In rats with adjuvant-induced arthritis, the enhanced production of MCP-1 and RANTES and the development of arthritis were suppressed by oral treatment with 100 mg/kg per day of KE-298 for 18 days. Furthermore, KE-298 (10–100 µg/ml) suppressed MCP-1 and RANTES production by IL-1β-stimulated RA synoviocytes through inhibition of NF-κB and AP-1 activation. These results suggest that the inhibitory effect of KE-298 on MCP-1 and RANTES production might partly explain its efficacy in rats with adjuvant-induced arthritis and in patients with RA.

Adjuvant-induced arthritis RA synoviocytes MCP-1 RANTES Transcription factors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  • Tomoyuki Inoue
    • 1
  • Miyuki Yamashita
    • 1
  • Megumu Higaki
    • 1
  1. 1.Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Kanagawa 216-8511, Japan

Personalised recommendations